ECOG4599 is the first to show that a large phase III clinical study of molecular targeted drugs combined with chemotherapy in the treatment
ECOG4599 is the first to show that a large phase III clinical study of molecular targeted drugs combined with chemotherapy in the treatment of lung cancer effectively, the first example is the anti angiogenesis drugs in the treatment of lung cancer with chemotherapy for successful cooperation.
The study of 878 cases of non squamous non-small cell lung cancer (NSCLC) treated with paclitaxel / carboplatin plus vascular endothelial growth factor (VEGF) inhibitor bevacizumab (CP+B) and pure paclitaxel / carboplatin (CP) chemotherapy were compared. The results showed that two of the median survival time was 12.5 months to 10.2 months, because with bevacizumab (Avastin) to improve survival for 2.3 months (P=0.007). In terms of survival, this is the best result of contemporary (third generation) chemotherapy in the treatment of advanced lung cancer, and it is also the result of the combination of antiangiogenic drugs and chemotherapy in molecular targeted therapy. The progression free survival was 6.4 months in the treatment group (P) for 4.5 months ()
Premature Ejaculation,Tumour,Hypertension,Depression,Tumour,Andrology Diseases,Tumour,Arthritis,Pain,Deaf,。 Cure999
Cure999 @ 2018